Video News

Overview of KEYNOTE-671 & NADIM II

September 6, 2023

1 min read

By Dr. Lei Deng

Watch Dr. Lei Deng’s overview of the KEYNOTE-671 and NADIM II trials, with important implications for non small cell lung cancer treatment!

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central Florida,

By: Zhiting Tang1, Lei Deng2 1. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug Administration

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug Administration

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug Administration